Amgen Inc. (AMGN) fair value analysis
S&P 500 & Nasdaq · Updated 2026-10-19
AMGN price how computed
Forward Fair Value verdict
OvervaluedAMGN is trading at a 10–25% premium to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $414.87
- Sector
- Healthcare
- 12-month range
- $291.16–$444.12
- Market cap
- $224B
- From 52-week high
- -6.6%
- Shares outstanding
- 541M
- Rank in Healthcare by discount to fair value
- #81 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
Amgen Inc. is a multinational biopharmaceutical company that discovers, develops, manufactures, and delivers human therapeutics with a focus on oncology, cardiovascular disease, inflammation, and bone health. The company operates globally with research, manufacturing, and distribution facilities across multiple continents serving patients in numerous countries worldwide.
AMGN currently ranks #81 of 108 Healthcare stocks by discount to fair value. It has screened as Overvalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $224B
- P/E (trailing)
- 19x
- Revenue (TTM)
- $38.1B
- Net margin
- 22.9%
- EPS (TTM)
- $22.37
- Gross margin
- 72.0%
- Debt / equity
- 4.90
- Revenue growth (3-yr avg)
- 15.2%
- Shares outstanding
- 541M
Derived indicators how computed
- Quality grade
- B
- Margin trend
- Expanding
- 52-week position
- The top quarter of its range
- DCF cross-check
- Overvalued
Technicals how computed
- RSI (14-day)
- 72 · overbought
- 50-day average
- $415.01
- 200-day average
- $368.90
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Dividends how computed
- Paid, last 12 months
- $9.94 per share (4 payments)
- Yield on last price
- 2.40%
- Consecutive years of increases
- 14
- Last ex-dividend date
- 2026-08-21
- Last payment date
- 2026-09-11
Earnings how computed
- Next earnings report
- 2026-11-03 (post-market)
- Last 8 quarters vs consensus
- 8 beat, 0 missed
- Quarter by quarter
- 2026-06 ▲ beat (+12.3%)
2026-03 ▲ beat (+8.0%)
2025-12 ▲ beat (+11.8%)
2025-09 ▲ beat (+12.6%)
2025-06 ▲ beat (+14.0%)
2025-03 ▲ beat (+15.0%)
2024-12 ▲ beat (+4.5%)
2024-09 ▲ beat (+9.2%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 12 buy · 17 hold · 5 sell (34 analysts)
- Consensus lean
- Hold-leaning
- Consensus price target
- $395
- Target vs last price
- -4.8%
What our data shows for AMGN
- Our model validated 17 trailing price-to-earnings windows for AMGN, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $291.16–$444.12.
- The 14-day relative strength index sits at an overbought 72.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for AMGN
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent AMGN news
TickrTrends' derived news-sentiment signal for AMGN is currently leaning positive, computed from recent coverage.
- Financial Exchanges CME, Cboe, ICE, Nasdaq Benefiting From Sector Rotation Out Of AI Stocks (investors.com, 2026-10-22)
TickrTrends take: Amgen operates in the Healthcare sector, which has historically benefited when investors rotate away from high-growth technology stocks like those in artificial intelligence. TickrTrends currently rates Amgen as overvalued, meaning that if sector rotation dynamics are driving capital toward Healthcare holdings, investors should monitor whether this rotation provides enough fundamental support to justify current valuations or whether Amgen's valuation premium persists despite the sectoral tailwinds. A valuation-focused reader should track whether Amgen's stock performance during this rotation period aligns with or diverges from its assessed overvalued status. - Amgen (AMGN) Sales Grew 10%, but Can Earnings Catch Up to the Price? (insidermonkey.com, 2026-10-21)
TickrTrends take: Amgen's 10% sales growth represents solid top-line momentum, but TickrTrends currently rates the stock as overvalued, suggesting that current pricing may not align with the company's earnings trajectory. For valuation-conscious investors in the Healthcare sector, the key question is whether earnings can accelerate sufficiently to justify the stock's current valuation levels or if there remains a gap between growth delivery and market price. This disconnect between sales performance and valuation assessment indicates that investors should monitor upcoming earnings reports to determine if profitability gains can narrow the overvaluation signal. - Amgen Inc (AMGN) Shares Surge 3.3% -- What GF Score of 85 Tells Investors (gurufocus.com, 2026-10-20)
TickrTrends take: Amgen shares recently gained ground, yet TickrTrends currently assesses the stock as overvalued based on its valuation analysis. The company's strong GF Score suggests operational quality and financial health, which can sometimes support higher valuations in the Healthcare sector, but this does not necessarily align with current market pricing according to the valuation framework. Investors focused on valuation metrics should monitor whether fundamental improvements or market conditions shift the overvalued assessment, particularly given the disconnect between quality indicators and current valuation levels.
More AMGN news
- Tonight’s Market Recap – October 20, 2026 (upsidetrader.com, 2026-10-20)
- Amgen Has the Drugs and the Dividend. Now It Needs the Growth (insidermonkey.com, 2026-10-19)
- Is AMGN Overvalued? DCF Says Worth $189 (gurufocus.com, 2026-10-19)
- SPDR Dow Jones Industrial Average ETF (DIA) Sells $31.3 Million More Goldman Sachs on Oct. 14 (gurufocus.com, 2026-10-16)
- What iShares Biotechnology ETF (IBB) Sold: Gilead Leads on Oct. 13 (gurufocus.com, 2026-10-15)
- A Look at Amgen Inc (AMGN) After 3.2% Gain -- GF Value $368.20 vs Price $426.11 (gurufocus.com, 2026-10-14)
- What SPDR Dow Jones Industrial Average ETF (DIA) Bought: GS Leads on Oct. 12 (gurufocus.com, 2026-10-14)
- AMGN Maintained by Guggenheim -- Price Target Lowered to $378 (gurufocus.com, 2026-10-13)
- Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy? (insidermonkey.com, 2026-10-13)
- iShares Biotechnology ETF (IBB) Adds Gilead and Amgen on Oct. 8 (gurufocus.com, 2026-10-12)
What people are saying
Follow the AMGN conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — AMGN's relative strength index moved from the neutral zone into overbought territory this week, indicating that the stock has experienced significant upward momentum. The Healthcare sector company maintains an overvalued status according to TickrTrends' derived indicators. The shift to overbought conditions suggests the stock may have risen sharply relative to its recent trading range.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for AMGN show a shift in trend dynamics this week. The 50/200-day trend state has moved from uptrend to mixed, signaling reduced momentum in the stock's near-term price direction relative to its longer-term trend. The current valuation verdict remains overvalued based on TickrTrends' assessment metrics.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is AMGN stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), AMGN is trading at a 10–25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.
What is AMGN's TickrTrends verdict?
AMGN's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.
How does AMGN compare to other Healthcare stocks?
AMGN ranks #81 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is AMGN overbought or oversold?
AMGN's 14-day RSI is in the overbought zone on TickrTrends' latest weekly data.
Does AMGN pay a dividend?
Yes. AMGN paid $9.94 per share over the last twelve months (4 payments), a 2.40% yield on TickrTrends' last price, and has raised the annual total for 14 consecutive years. The last ex-dividend date was 2026-08-21.
When does AMGN report earnings next?
AMGN's next earnings report is scheduled for 2026-11-03 (post-market), per the published earnings calendar.
Does AMGN usually beat earnings estimates?
Over its last 8 reported quarters AMGN beat the consensus estimate 8 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about AMGN?
Of 34 analysts covering AMGN, 12 rate it a buy, 17 a hold and 5 a sell - hold-leaning, with a consensus price target of $395 (-4.8% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
AMGN vs ABBV · AMGN vs AZTA · AMGN vs BIO · AMGN vs DGX · AMGN vs GILD